SCHEMBL2952288

SCHEMBL2952288

Oc1n[nH]c2c1CCN(Cc1ccccc1)C2

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 1/20 0.56
ACHE P22303 2/20 0.48
SIGMAR1 Q99720 1/20 0.46
BRS3 P32247 7/20 0.45
GAA P10253 3/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
ATM Q13315 1/20 0.44
GLA P06280 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
PNMT P11086 1/20 0.44
ADORA1 P30542 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3389927 0.78 SLC6A5 (0.51) SLC6A5ACHEBRS3KDM4EALDH1A1
SCHEMBL4946012 0.75 ACHE (0.51) SLC6A5ACHEBRS3KMT2AADORA1
SCHEMBL17877207 0.74 BRD4 (0.56) SLC6A5ACHELMNA
SCHEMBL28901842 0.73 SLC6A5 (0.45) SLC6A5ACHESIGMAR1GAALMNA
SCHEMBL19616715 0.72 KMT2A (0.50) SLC6A5GAAKDM4EALDH1A1KMT2A
SCHEMBL4079977 0.72 LIMK1 (0.49) SLC6A5ACHESIGMAR1GAAKDM4E
SCHEMBL22492316 0.72 BRS3 (0.56) SLC6A5BRS3GAAKDM4EALDH1A1
SCHEMBL4144313 0.72 SLC6A5 (1.00) SLC6A5ACHEGAAKDM4EALDH1A1
SCHEMBL3932572 0.72 FAAH (0.54) SLC6A5SIGMAR1GAAKDM4EALDH1A1
SCHEMBL4988290 0.72 LMNA (0.46) SLC6A5ACHESIGMAR1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP disclosed
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US disclosed
WO-2010015657-A2 NEW ALKOXYPYRAZOLES INSTITUT PASTEUR (FR) 2010-02-11 WO disclosed
EP-2151433-A1 Alkoxypyrazoles and the process for their preparation Institut Pasteur (FR) 2010-02-10 EP disclosed
EP-1856058-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-11-21 EP disclosed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 WO disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 SLC6A5 4826/4885ACHE 2729/4885SIGMAR1 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.